Maravai LifeSciences Holdings, Inc. reported $209M of revenue over the trailing twelve months, −5.0% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $209M (to Q2 2026). Net income: −$77M, trailing twelve months to Q2 2026. Free cash flow: −$36M, trailing twelve months to Q2 2026. Operating margin: −62%, trailing twelve months to Q2 2026.

MRVIMaravai LifeSciences Holdings, Inc.

Healthcare

$7.47+177% 1Y

$7.47

$2.6952 weeks$8.99

MRVI as reported

Maravai LifeSciences Holdings, Inc. reported $209M of revenue over the trailing twelve months, −5.0% on the year before. 11 reported series are charted on this page, each one as filed.

$209M

Revenue, trailing twelve months · to Q2 2026 · −5.0% against the twelve months before

Net income: −$77M
Net income · −60% year on year · trailing twelve months to Q2 2026
Free cash flow: −$36M
Free cash flow · −17% year on year · trailing twelve months to Q2 2026
Operating margin: −62%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for MRVI, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$209M	−5.0%	Q2 2026
Net income	−$77M	−60%	Q2 2026
EPS	−$0.52	−61%	Q2 2026
Gross margin	33%	n/a	Q2 2026
Operating margin	−62%	n/a	Q2 2026
Net margin	−41%	n/a	Q2 2026
ROE	−50%	n/a	Q2 2026
ROA	−15%	n/a	Q2 2026
ROIC	−48%	n/a	Q2 2026
Free cash flow	−$36M	−17%	Q2 2026
P/E	22.9	n/a	Q3 2023 · 11 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.